Delpharm Set to Transform Boucherville Facility After Securing Government Funding
This latest funding will bolster the additional investment and private capital and will allow Delpharm to modernize its Boucherville facility to be able to meet the growing demand for injectable drugs.
French headquartered, global CDMO, Delpharm, has announced that it has received financial support from the Québec government to help with its plans to modernize its facility in Boucherville, Québec, Canada. The provincial government’s contribution of CAD 60 million was unveiled by the Economy, Innovation, and Energy Minister Christine Fréchette, and Health Minister Christian Dubé (1).
“I’m proud to announce this CAD 60-million investment in a company that contributes to the prosperity of Québec’s life sciences sector,” said Christine Fréchette, Minister of Economy, Innovation, and Energy, and Minister Responsible for Regional Economic Development, in a company press release about the investment (1). “By partnering with Delpharm and investing in its success, our government is ensuring our supply chains are strengthened and demand from the hospital market is sustained. This partnership will positively impact our healthcare system, and Québec’s strategic position in the pharmaceutical sector.”
In addition to the provincial government money, Delpharm has been previously granted CAD 60 million from the federal Canadian government and has also raised CAD 100 million in private capital, making the total amount raised CAD 220 million. With these funds, Delpharm plans to transform its Boucherville site into a world-class pharmaceutical facility by 2031.
To modernize the facility, the company plans to expand the plant and install a new state-of-the-art sterile filling line. Additionally, nearly all (95%) of the equipment housed within the facility will be replaced and the production capacity will be increased so that the company can meet the growing demand for injectable drugs.
“Delpharm is a strategic supplier to Québec’s healthcare network, which makes heavy use of the products designed by the Boucherville-based company. Its manufacturing site is the largest sterile injectable drug production facility in Canada, supplying a significant portion to the Québec and Canadian markets,” added Christian Dubé, Minister of Health, in the press release (1). “This investment will allow Delpharm to bolster its innovation and production capacity. Congratulations to Delpharm on this promising expansion!”
According to a study commissioned by Delpharm’s partner, Sandoz, the Boucherville site has an integral role in the Canadian healthcare system, producing 20 of the 100 most important medicines for the country. Additionally, Delpharm has estimated that 3,000 doses of the sterile injectable drugs produced at its Boucherville site are administered to patients in Québec every hour (1).
“We would like to acknowledge the commitment of the Ministry of Economy, Innovation and Energy, a key partner in strengthening Québec’s pharmaceutical autonomy,” commented Mathieu Grondin, Site Director at Delpharm Boucherville, in the press release. “We also wish to recognize our long-standing partner Sandoz, with whom we have renewed a 10-year contract to produce generic hospital medicines. This agreement guarantees patients in Québec and across Canada a local, stable, and reliable supply.”
Through the modernization of the Boucherville facility, Delpharm expects to be able to provide tangible benefits to the local region, including the preservation of over 500 specialized jobs and an injection of CAD 100 million annually into the economy as a result of salaries and supplier purchases. Additionally, the company will repay CAD 105 million of the government funding over time and will also contribute dividends to the Québec government.
Reference
1. Delpharm. Delpharm Secures Major Québec Government Support to Modernize its Boucherville Facility. Press Release, Aug. 26, 2025.